T6403

BAF312 (Siponimod (BAF-312)), a next-generation S1P receptor modulator, is specific for S1P1 and S1P5 receptors with EC50 of 0.39 nM and 0.98 nM, respectively. The specificity of BAF312 for S1P1 and S1P5 receptors exhibits >1000-fold over S1P2, S1P3 and S1P4 receptors.

EGFR-IN-31 is a potent inhibitor of EGFR, which is associated with uncontrolled cell growth due to overexpression and mutation of the epidermal growth factor receptor (EGFR), particularly in most cancer diseases such as NSCLC. EGFR-IN-31 exhibits research potential for EGFR mutation-related diseases.

KRAS G12D inhibitor 9 is a potent agent targeting KRAS G12D, an important member of the RAS protein family involved in intracellular signaling crucial for growth and development. This inhibitor shows significant research potential for KRAS G12D-mediated cancer.

CYP3A4-IN-3 is a specific, highly affinity cytochrome P450 3A4 (CYP3A4) (cytochrome P450 3A4 (CYP3A4)) inhibitor (IC50: 0.075 μM). CYP3A4-IN-3 is an analogue of ritonavir with a simpler structure and twice as much inhibition as ritonavir. CYP3A4-IN-3 can be used as an antiviral agent and immunosuppressant.

KRAS G12C inhibitor 34 is an inhibitor of KRAS G12C that can be used to study cancer research.

Antitumor agent-45 has an inhibitory effect on c-Met expression and is able to block A549 cells in the G0/G1 and G2/M phases and induce apoptosis.

Antitrypanosal agent 5 is a selective anti-trypanosomal agent that acts on T. brucei (IC50: 1 nM) and HEK293 cells (IC50: 483.3 μM).

5-HT6R/MAO-B modulator 1 is an antagonist of 5-HT6R (at Gs signaling) and an irreversible inhibitor of MAO-B that exhibits glial protective activity and induces scopolamine-induced memory deficits.

CYP3A4-IN-2 is a specific inhibitor of cytochrome P450 3A4 (CYP3A4) (IC50: 0.055 μM). As a ritonavir analogue with a more hydrophobic R2 side group, CYP3A4-IN-2 exhibits stronger inhibition than ritonavir and is capable of acting as an immunosuppressive and antiviral agent.